Incyte Corp.

Incyte Corp.

Incyte Corp.

Overview
Date Founded

1991

Headquarters

1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803

Type of Company

Public

Employees (Worldwide)

1,773

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Contact Data
Trying to get in touch with decision makers at Incyte Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chairman, President & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Secretary, Executive Vice President & General Counsel

Executive Vice President & Chief Scientific Officer

Vice President, Finance & Chief Accounting Officer

Chief Medical Officer & Executive Vice President

Executive Vice President & General Manager, North America

Executive Vice President & General Manager, Europe

Head-Clinical Development & General Manager-Japan

Board of Directors

Chairman, President & Chief Executive Officer at Incyte Corp.

Managing Member at Baker Bros. Advisors GP LLC

Chief Executive Officer at Agios Pharmaceuticals, Inc.

Former Senior Vice President of Finance at Biogen MA, Inc.

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Senior Advisor at The Monitor Group, Inc. - Georgia

Former Senior Vice President-Worldwide Safety & Regulatory at Pfizer, Inc.

Director & President-Therapeutics at Asklepios BioPharmaceutical, Inc.

Paths to Incyte Corp.
Potential Connections via
Relationship Science
You
Incyte Corp.
Owners & Shareholders
Details Hidden

BBA pursues a fundamentally-driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities.

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

HCM’s funds pursue a fundamental-driven long/short equity strategy with a primary focus on the global healthcare and life sciences sector. They use a bottom-up fundamental selection of best long and short ideas. The firm conducts daily monitoring of top-down, portfolio-level analysis, including the following: concentration of investments: liquidity; price target and stop loss monitoring, leverage, and hedging. In addition, HCM has adopted a Socially Responsible Investment Policy outlining their practical integration of environmental, social and governance (ESG) considerations into their investment process.

Recent Transactions
Details Hidden

Incyte Corp. issued USD Common Stock

Details Hidden

Incyte Corp. purchases Incyte Biosciences Luxembourg SARL from ARIAD Pharmaceuticals, Inc.

Details Hidden

Incyte Corp. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Accountant

Advised onIncyte Corp. purchases Proteome, Inc.

Underwriter

Advised onIncyte Corp. issued USD Common Stock

Underwriter

Advised onIncyte Corp. issued USD Common Stock

Managing Director

Advised onIncyte Corp. issued USD Common Stock

Associate

Advised onIncyte Corp. purchases Incyte Biosciences Luxembourg SARL from ARIAD Pharmaceuticals, Inc.

Legal Advisor

Advised onIncyte Corp. purchases Incyte Biosciences Luxembourg SARL from ARIAD Pharmaceuticals, Inc.

Advisors & Consultants
Legal Advisor

Former Partner at Fenwick & West LLP

Legal Advisor

Former Senior Partner at Pillsbury Winthrop Shaw Pittman LLP

Clients

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. Its products include sintilimab (IBI-308), a novel PD-1 antibody; IBI-305, the bevacizumab (Avastin) biosimilar; IBI-301, the rituximab (MabThera/Rituxan) biosimilar; and IBI-303, the (Humira) biosimilar. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.

Key Stats and Financials As of 2020
Market Capitalization
$17B
Total Enterprise Value
$17.2B
Earnings Per Share
$-1.36
Revenue
$2.67B
Net Profit
$-296M
EBITDA
$-188M
EBITDAMargin
-7.07%
Total Debt
$61.7M
Total Equity
$2.61B
Enterprise Value / Sales
6.46x
TEVNet Income
-58.26x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
20.18%
Non-Profit Donations & Grants
Investments
Details Hidden

De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom.

Details Hidden

Genomic Health, a global health company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions. At Genomic Health, we developed and follow a highly specialized process that not only adheres rigorously to CAP (College of American Pathologists) standards and CLIA (Clinical Laboratory Improvement Amendments) regulations, but also incorporates numerous real-time quality checks and periodic proficiency testing designed to produce a high level of accuracy in information that we deliver to physicians and patients.

Details Hidden

Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA.

Suppliers
Agenus Inc. Medical Support Services | Lexington, MA

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Merus NV Biotechnology | Utrecht, Netherlands

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Calithera Biosciences, Inc. Biotechnology | South San Francisco, CA

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Competitors
Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Incyte Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Incyte Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Incyte Corp..